Liu X, et al. - Via 16 trials with 1,607 patients with type 2 diabetes mellitus (T2DM), researchers evaluated the effect of dipeptidyl peptidase-4 inhibitors (DPP-4i) on modulating serum levels of C-reactive protein (CRP). Serum CRP concentrations were notably decreased by DPP-4i. An association between the change in serum concentrations of CRP and brief diabetes duration, during subgroup analysis, was noted. Further, favorable anti-inflammatory effects against diabetes and atherosclerosis were manifested by DDP-4i by targeting proteins contributing to inflammatory pathways. A reduction in serum CRP resulted from DDP-4i, which had no stronger impact than traditional oral antidiabetic agents.